Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Breast 2Tumor-Agnostic 1Head & Neck 1Gynecologic 1

Conditions

Nasopharyngeal Carcinoma 23Squamous Cell Carcinoma of Head and Neck 14Nasopharyngeal Neoplasms 3Mouth Neoplasms 2Hypopharyngeal Neoplasms 2Head and Neck Neoplasms 2Thyroid Neoplasms 1Salivary Gland Neoplasms 1Neoplasm Metastasis 1Laryngeal Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

pembrolizumab 35Cetuximab 18Gemcitabine 14Nivolumab 13Cisplatin 13Paclitaxel 10Carboplatin 9Cyclophosphamide 7cemiplimab 6Fluorouracil 6Specimen Handling 5Magnetic Resonance Spectroscopy 5Docetaxel 5fludarabine 4durvalumab 4aldesleukin 4Immune Checkpoint Inhibitors 4Biopsy 4fludarabine phosphate 3Valproic Acid 3Radiation 3Interleukin-2 3Drug Therapy 3Bevacizumab 3130-nm albumin-bound paclitaxel 3tislelizumab 2sintilimab 2avelumab 2apatinib 2Tablets 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × camrelizumab × Head & Neck × Clear all
NCT05854849 2023-05-11

Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC

Sun Yat-sen University

Phase 3 Recruiting
244 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡